3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Enrolling by invitation
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Fasting
9
Prostatic Neoplasms
3
Breast Neoplasms
3
Intermittent Fasting
2
Polycystic Ovary Syndrome
1
Ovarian Neoplasms
1
Neoplasms
1
Lymphoma
1
Infertility
1
Glioma
1
Fibrosis
1
Fasting in Malignant Solid Tumors
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Childhood Cancer Survivors
1
Interventions
Cyclophosphamide
297
Rituximab
272
Etoposide
149
Filgrastim
142
fludarabine phosphate
120
Cytarabine
109
Vincristine
107
Melphalan
102
Radiotherapy
101
Doxorubicin
97
Peripheral Blood Stem Cell Transplantation
93
Methotrexate
91
fludarabine
86
Prednisone
86
Busulfan
86
Tacrolimus
66
Mycophenolic Acid
62
Granulocyte Colony-Stimulating Factor
60
Antilymphocyte Serum
58
Dexamethasone
57
Whole-Body Irradiation
55
Carmustine
54
Bortezomib
45
Cyclosporine
44
Lenalidomide
41
Methylprednisolone
40
sargramostim
39
Bendamustine Hydrochloride
37
ibritumomab tiuxetan
34
Ifosfamide
34
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Lymphoma
×
Angptl4 protein, mouse
×
Clear all
NCT06645093
2026-03-10
FasteStudien
University of Oslo
Phase NA
Enrolling by invitation
40 enrolled